Syngene International Limited (SYNGENE.BO)
INR 850.8
(-1.08%)
INR 850.8
(-1.08%)
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2023 | 5.55 Billion INR | -31.89% |
| 2022 | 8.15 Billion INR | -20.2% |
| 2021 | 10.21 Billion INR | 14.41% |
| 2020 | 8.92 Billion INR | 15.53% |
| 2019 | 7.72 Billion INR | -4.97% |
| 2018 | 8.13 Billion INR | 3.29% |
| 2017 | 7.87 Billion INR | -5.44% |
| 2016 | 8.32 Billion INR | -6.54% |
| 2015 | 8.91 Billion INR | 443.29% |
| 2014 | 1.64 Billion INR | 9.12% |
| 2013 | 1.5 Billion INR | 3240.0% |
| 2012 | 45 Million INR | -95.78% |
| 2011 | 1.06 Billion INR | -38.38% |
| 2010 | 1.73 Billion INR | -15.49% |
| 2009 | 2.04 Billion INR | 0.0% |
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2024 Q2 | 1.59 Billion INR | 9.49% |
| 2024 Q1 | 5.81 Billion INR | 4.76% |
| 2023 Q2 | 8.33 Billion INR | -5.29% |
| 2023 Q1 | 8.79 Billion INR | 7.89% |
| 2023 FY | 5.55 Billion INR | -31.89% |
| 2023 Q4 | 5.55 Billion INR | -21.58% |
| 2023 Q3 | 7.08 Billion INR | -15.01% |
| 2022 Q3 | 10.51 Billion INR | 4.25% |
| 2022 Q1 | 9.81 Billion INR | -3.94% |
| 2022 FY | 8.15 Billion INR | -20.2% |
| 2022 Q2 | 10.09 Billion INR | 2.82% |
| 2022 Q4 | 8.15 Billion INR | -22.5% |
| 2021 Q1 | 9.04 Billion INR | 1.27% |
| 2021 Q2 | 8.83 Billion INR | -2.29% |
| 2021 Q3 | 8.84 Billion INR | 0.08% |
| 2021 FY | 10.21 Billion INR | 14.41% |
| 2021 Q4 | 10.21 Billion INR | 15.54% |
| 2020 Q3 | - INR | -100.0% |
| 2020 Q4 | 8.92 Billion INR | 0.0% |
| 2020 Q1 | - INR | -100.0% |
| 2020 Q2 | 7.77 Billion INR | 0.0% |
| 2020 FY | 8.92 Billion INR | 15.53% |
| 2019 Q2 | 7.46 Billion INR | 0.0% |
| 2019 FY | 7.72 Billion INR | -4.97% |
| 2019 Q1 | - INR | -100.0% |
| 2019 Q4 | 7.72 Billion INR | 0.0% |
| 2019 Q3 | - INR | -100.0% |
| 2018 Q4 | 8.13 Billion INR | 0.0% |
| 2018 FY | 8.13 Billion INR | 3.29% |
| 2018 Q3 | - INR | -100.0% |
| 2018 Q1 | - INR | -100.0% |
| 2018 Q2 | 8.35 Billion INR | 0.0% |
| 2017 Q4 | 7.87 Billion INR | 2.26% |
| 2017 FY | 7.87 Billion INR | -5.44% |
| 2017 Q3 | 7.7 Billion INR | -3.55% |
| 2017 Q1 | - INR | -100.0% |
| 2017 Q2 | 7.98 Billion INR | 0.0% |
| 2016 Q3 | - INR | -100.0% |
| 2016 Q2 | 9.22 Billion INR | 0.0% |
| 2016 FY | 8.32 Billion INR | -6.54% |
| 2016 Q4 | 8.32 Billion INR | 0.0% |
| 2016 Q1 | - INR | -100.0% |
| 2015 FY | 8.91 Billion INR | 443.29% |
| 2015 Q2 | 2.12 Billion INR | 0.0% |
| 2015 Q1 | - INR | -100.0% |
| 2015 Q4 | 8.91 Billion INR | 284.05% |
| 2015 Q3 | 2.32 Billion INR | 9.33% |
| 2014 FY | 1.64 Billion INR | 9.12% |
| 2014 Q1 | - INR | 0.0% |
| 2014 Q4 | 1.64 Billion INR | -10.53% |
| 2014 Q3 | 1.83 Billion INR | 0.0% |
| 2013 FY | 1.5 Billion INR | 3240.0% |
| 2012 FY | 45 Million INR | -95.78% |
| 2011 FY | 1.06 Billion INR | -38.38% |
| 2010 FY | 1.73 Billion INR | -15.49% |
| 2009 FY | 2.04 Billion INR | 0.0% |
| Name | Total Debt | Total Debt Difference |
|---|---|---|
| Alfavision Overseas (India) Limited | 1.35 Billion INR | -309.291% |
| Biocon Limited | 162.76 Billion INR | 96.589% |
| Blue Jet Healthcare Limited | 16.12 Million INR | -34320.337% |
| Concord Biotech Limited | 97.37 Million INR | -5601.61% |
| Dishman Carbogen Amcis Limited | 23.12 Billion INR | 75.992% |
| FERMENTA BIOTECH LIMITED | 1.32 Billion INR | -319.745% |
| GENOMIC VALLEY BIOTECH LIMITED | - INR | -Infinity% |
| Lyka Labs Limited | 586.5 Million INR | -846.631% |
| Panacea Biotec Limited | 209.9 Million INR | -2545.069% |
| SAMSRITA LABS LIMITED | 22.03 Million INR | -25099.71% |
| Servoteach Industries Limited | 5059.00 INR | -109744908.895% |
| SMS Lifesciences India Limited | 1 Billion INR | -451.21% |
| Supriya Lifescience Limited | 54.88 Million INR | -10016.618% |
| TAKE Solutions Limited | 370.85 Million INR | -1397.101% |
| Titan Biotech Limited | 83.02 Million INR | -6586.82% |
| Transgene Biotek Limited | 140.01 Million INR | -3865.431% |
| Vanta Bioscience Limited | 609.53 Million INR | -810.857% |